CA3010862A1 - Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques - Google Patents

Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques Download PDF

Info

Publication number
CA3010862A1
CA3010862A1 CA3010862A CA3010862A CA3010862A1 CA 3010862 A1 CA3010862 A1 CA 3010862A1 CA 3010862 A CA3010862 A CA 3010862A CA 3010862 A CA3010862 A CA 3010862A CA 3010862 A1 CA3010862 A1 CA 3010862A1
Authority
CA
Canada
Prior art keywords
antibody
vegf
drug
aflibercept
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3010862A
Other languages
English (en)
Inventor
Samirkumar PATEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clearside Biomedical Inc
Original Assignee
Clearside Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearside Biomedical Inc filed Critical Clearside Biomedical Inc
Publication of CA3010862A1 publication Critical patent/CA3010862A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes et des dispositifs pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA) humide, la néovascularisation choroïdienne (CNV), la DMLA humide associée à la CNV et/ou la DMLA humide associée à l'occlusion veineuse rétinienne (RVO) chez un sujet humain qui en a besoin. Selon certains aspects, les dispositifs décrits dans la présente description comprennent un récipient de médicament délimitant une lumière conçue pour contenir un médicament, une partie terminale distale du récipient de médicament comprenant une partie d'accouplement conçue pour être accouplée amovible à un ensemble aiguille, une partie terminale proximale du récipient de médicament comprenant un rebord et un épaulement longitudinal ; un ensemble piston comprenant une partie terminale distale disposée mobile à l'intérieur de la lumière du récipient de médicament ; et une poignée accouplée à une partie terminale proximale de l'ensemble piston.
CA3010862A 2016-01-08 2017-01-09 Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques Abandoned CA3010862A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276543P 2016-01-08 2016-01-08
US62/276,543 2016-01-08
US201662324708P 2016-04-19 2016-04-19
US62/324,708 2016-04-19
PCT/US2017/012757 WO2017120601A1 (fr) 2016-01-08 2017-01-09 Méthodes et dispositifs pour le traitement de troubles oculaires postérieurs avec l'aflibercept et d'autres substances biologiques

Publications (1)

Publication Number Publication Date
CA3010862A1 true CA3010862A1 (fr) 2017-07-13

Family

ID=59274052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010862A Abandoned CA3010862A1 (fr) 2016-01-08 2017-01-09 Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques

Country Status (9)

Country Link
EP (1) EP3400014A1 (fr)
JP (1) JP2019501200A (fr)
KR (1) KR20180101488A (fr)
CN (1) CN108778330A (fr)
AU (1) AU2017206114A1 (fr)
BR (1) BR112018013805A2 (fr)
CA (1) CA3010862A1 (fr)
MX (1) MX2018008469A (fr)
WO (1) WO2017120601A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
EP2627292B1 (fr) 2010-10-15 2018-10-10 Clearside Biomedical, Inc. Dispositif pour accès oculaire
SG11201503637SA (en) 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
CN105246529B (zh) 2013-05-03 2019-06-14 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
EP3003454B1 (fr) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Appareil pour une administration de médicament à l'aide de multiples réservoirs
CA2918419C (fr) 2013-07-23 2022-05-03 Novaliq Gmbh Compositions d'anticorps stabilisees
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
IL260323B1 (en) 2015-12-30 2024-09-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3452103A1 (fr) 2016-04-15 2019-03-13 The Trustees Of The University Of Pennsylvania Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
WO2017192565A1 (fr) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systèmes et méthodes pour l'administration de médicaments par voie ophtalmique
WO2018031913A1 (fr) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Dispositifs et procédés de réglage de la profondeur d'insertion d'une aiguille pour administration de médicament
WO2018204515A1 (fr) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Procédés d'administration ciblée de médicament au moyen d'une microaiguille
SG11202002396TA (en) * 2017-09-27 2020-04-29 Regenxbio Inc Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
SG11202005719UA (en) * 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
CA3099551A1 (fr) * 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. Formulations contenant des proteines de fusion du recepteur vegf a haute concentration
CN110693886B (zh) * 2018-07-09 2022-12-06 天津医科大学 防治脑海绵状血管畸形病变的药物
US20220143137A1 (en) * 2019-02-13 2022-05-12 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
KR20200101160A (ko) * 2019-02-19 2020-08-27 전남대학교산학협력단 리보세라닙을 포함하는 안구 신생혈관 억제용 약학 조성물 및 이를 이용한 안구 신생혈관 억제 방법
AU2020253462A1 (en) * 2019-04-03 2021-10-28 Regenxbio Inc. Gene therapy for eye pathologies
CN110522909B (zh) * 2019-09-30 2024-02-20 安徽省立医院 一种协同增强抗her2阳性肿瘤效果的药物组合
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023500385A (ja) * 2019-11-11 2023-01-05 シーストーン・ファーマシューティカルズ・（スージョウ）・カンパニー・リミテッド 医薬組合せ物およびその使用
EP4106755A4 (fr) * 2020-02-19 2024-03-27 Clearside Biomedical, Inc. Compositions comprenant de l'axitinib et méthodes de traitement de troubles oculaires
EP4164593A1 (fr) * 2020-06-15 2023-04-19 OPKO Pharmaceuticals, LLC Formulations ophtalmiques topiques à base de liposomes chargés d'acétonide de triamcinolone en tant que thérapie primaire pour un ?dème maculaire secondaire à une occlusion de la veine rétinienne ramifiée
MX2023013554A (es) * 2021-05-17 2023-11-29 Regeneron Pharma Regimenes de antagonistas del vegf en dosis alta extendidos para el tratamiento de trastornos oculares angiogenicos.
CN113546176B (zh) * 2021-06-30 2024-03-15 南通大学 一种特异性用于抑制眼内血管新生药物合成方法
CN118356501A (zh) * 2023-01-19 2024-07-19 百奥泰生物制药股份有限公司 一种复方制剂及其应用
WO2024167694A2 (fr) * 2023-02-06 2024-08-15 Celularity Inc. Matrices extracellulaires placentaires pour l'administration oculaire d'agents thérapeutiques ophtalmiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201249459A (en) * 2011-05-27 2012-12-16 Novartis Ag Method of treating vision disorders
CA2865132A1 (fr) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions et procedes pour administration oculaire d'un agent therapeutique
SG11201503637SA (en) * 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
CA2933900A1 (fr) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Preparations et procedes servant a introduire de maniere ciblee des agents therapeutiques dans l'ƒil
US20180042765A1 (en) * 2014-06-17 2018-02-15 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorders

Also Published As

Publication number Publication date
EP3400014A1 (fr) 2018-11-14
AU2017206114A1 (en) 2018-08-02
WO2017120601A1 (fr) 2017-07-13
BR112018013805A2 (pt) 2018-12-11
KR20180101488A (ko) 2018-09-12
MX2018008469A (es) 2018-11-09
CN108778330A (zh) 2018-11-09
JP2019501200A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
US20210260047A1 (en) Methods and devices for the treatment of ocular diseases in human subjects
KR102511477B1 (ko) 안구 후부 질환을 치료하기 위한 방법 및 디바이스
CA3010862A1 (fr) Methodes et dispositifs pour le traitement de troubles oculaires posterieurs avec l'aflibercept et d'autres substances biologiques
US20220280341A1 (en) Apparatus and methods for drug delivery using microneedles

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831